Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins

Life Sciences

Volumn 86, Issue 13-14, 2010, Pages 532-537

  Zhou, Jie ^a   Wang, Hongxing ^b   Feng, Youmei ^a   Chen, Juan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b inGenious Targeting Laboratory Inc   (United States)

Author keywords

Alzheimer's disease; Axonal transport; Cyclin dependent kinase 5; Neurofilament; Phosphorylation; Tau

Indexed keywords

CYCLIN DEPENDENT KINASE 5; ENHANCED GREEN FLUORESCENT PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN P25; ROSCOVITINE; TAU PROTEIN; NERVE PROTEIN; P25 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CELL ASSAY; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSFECTION; NERVE FIBER TRANSPORT; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIKARYON; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PLASMID; TUMOR CELL LINE; WESTERN BLOTTING;

AXONAL TRANSPORT; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 5; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; NERVE TISSUE PROTEINS; NEUROFILAMENT PROTEINS; PHOSPHORYLATION; PLASMIDS; PROTEIN KINASE INHIBITORS; PURINES; TAU PROTEINS;

EID: 77950555100     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.02.009     Document Type: Article

References (36)

1. Ackerley S., Thornhill P., Grierson A.J., Brownlees J., Anderton B.H., Leigh P.N., Shaw C.E., Miller C.C. Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments. Journal of Cell Biology 2003, 161(3):489-495.
2. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., Nelson R.B., McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(6):2910-2915.
3. Archer D.R., Watson D.F., Griffin J.W. Phosphorylation-dependent immunoreactivity of neurofilaments and the rate of slow axonal transport in the central and peripheral axons of the rat dorsal root ganglion. Journal of Neurochemistry 1994, 62(3):1119-1125.
4. Bajaj N.P. Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2000, 1(5):319-327.
5. Bennecib M., Gong C.X., Grundke-Iqbal I., Iqbal K. Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Letters 2000, 485(1):87-93.
6. Camins A., Verdaguer E., Folch J., Canudas A.M., Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News & Perspectives 2006, 19(8):453-460.
7. de la Monte S.M., Wands J.R. Diagnostic utility of quantitating neurofilament-immunoreactive Alzheimer's disease lesions. Journal of Histochemistry and Cytochemistry 1994, 42(12):1625-1634.
8. Fu A.K., Fu W.Y., Cheung J., Tsim K.W., Ip F.C., Wang J.H., Ip N.Y. Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nature Neuroscience 2001, 4(4):374-381.
9. Gao C.Y., Zakeri Z., Zhu Y., He H., Zelenka P.S. Expression of Cdk5, p35, and Cdk5-associated kinase activity in the developing rat lens. Developmental Genetics 1997, 20(3):267-275.
10. Gong C.X., Wang J.Z., Iqbal K., Grundke-Iqbal I. Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neuroscience Letters 2003, 340(2):107-110.
11. Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Gotz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(41):15997-16002.
12. Jung C., Shea T.B. Regulation of neurofilament axonal transport by phosphorylation in optic axons in situ. Cell Motility and the Cytoskeleton 1999, 42(3):230-240.
13. Kobayashi S., Ishiguro K., Omori A., Takamatsu M., Arioka M., Imahori K., Uchida T. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Letters 1993, 335(2):171-175.
14. LaPointe N.E., Morfini G., Pigino G., Gaisina I.N., Kozikowski A.P., Binder L.I., Brady S.T. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. Journal of Neuroscience Research 2009, 87(2):440-451.
15. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405(6784):360-364.
16. Leroy K., Boutajangout A., Authelet M., Woodgett J.R., Anderton B.H., Brion J.P. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathologica 2002, 103(2):91-99.
17. Liao X., Zhang Y., Wang Y., Wang J. The effect of cdk-5 overexpression on tau phosphorylation and spatial memory of rat. Science in China Series C: Life Sciences 2004, 47(3):251-257.
18. Lichtenberg-Kraag B., Mandelkow E.M., Biernat J., Steiner B., Schroter C., Gustke N., Meyer H.E., Mandelkow E. Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(12):5384-5388.
19. Maccioni R.B., Otth C., Concha I.I., Munoz J.P. The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. European Journal of Biochemistry 2001, 268(6):1518-1527.
20. Miller C.C., Ackerley S., Brownlees J., Grierson A.J., Jacobsen N.J., Thornhill P. Axonal transport of neurofilaments in normal and disease states. Cellular and Molecular Life Sciences 2002, 59(2):323-330.
21. Moran C.M., Donnelly M., Ortiz D., Pant H.C., Mandelkow E.M., Shea T.B. Cdk5 inhibits anterograde axonal transport of neurofilaments but not that of tau by inhibition of mitogen-activated protein kinase activity. Molecular Brain Research 2005, 134(2):338-344.
22. Niethammer M., Smith D.S., Ayala R., Peng J., Ko J., Lee M.S., Morabito M., Tsai L.H. NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron 2000, 28(3):697-711.
23. Nikolic M., Dudek H., Kwon Y.T., Ramos Y.F., Tsai L.H. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes & Development 1996, 10(7):816-825.
24. Nikolic M., Chou M.M., Lu W., Mayer B.J., Tsai L.H. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 1998, 395(6698):194-198.
25. Nixon R.A., Lewis S.E., Mercken M., Sihag R.K. [32P]orthophosphate and [35S]methionine label separate pools of neurofilaments with markedly different axonal transport kinetics in mouse retinal ganglion cells in vivo. Neurochemical Research 1994, 19(11):1445-1453.
26. Nixon R.A., Paskevich P.A., Sihag R.K., Thayer C.Y. Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo: influences on regional neurofilament accumulation, interneurofilament spacing, and axon caliber. Journal of Cell Biology 1994, 126(4):1031-1046.
27. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402(6762):615-622.
28. Shea T.B., Yabe J.T., Ortiz D., Pimenta A., Loomis P., Goldman R.D., Amin N., Pant H.C. Cdk5 regulates axonal transport and phosphorylation of neurofilaments in cultured neurons. Journal of Cell Science 2004, 117(Pt 6):933-941.
29. Shea T.B., Zheng Y.L., Ortiz D., Pant H.C. Cyclin-dependent kinase 5 increases perikaryal neurofilament phosphorylation and inhibits neurofilament axonal transport in response to oxidative stress. Journal of Neuroscience Research 2004, 76(6):795-800.
30. Sternberger N.H., Sternberger L.A., Ulrich J. Aberrant neurofilament phosphorylation in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1985, 82(12):4274-4276.
31. Strack S., Westphal R.S., Colbran R.J., Ebner F.F., Wadzinski B.E. Protein serine/threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments. Molecular Brain Research 1997, 49(1-2):15-28.
32. Wang J., Tung Y.C., Wang Y., Li X.T., Iqbal K., Grundke-Iqbal I. Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Letters 2001, 507(1):81-87.
33. Watson D.F., Griffin J.W., Fittro K.P., Hoffman P.N. Phosphorylation-dependent immunoreactivity of neurofilaments increases during axonal maturation and beta, beta'-iminodipropionitrile intoxication. Journal of Neurochemistry 1989, 53(6):1818-1829.
34. Watson D.F., Hoffman P.N., Fittro K.P., Griffin J.W. Neurofilament and tubulin transport slows along the course of mature motor axons. Brain Research 1989, 477(1-2):225-232.
35. Watson D.F., Fittro K.P., Hoffman P.N., Griffin J.W. Phosphorylation-related immunoreactivity and the rate of transport of neurofilaments in chronic 2, 5-hexanedione intoxication. Brain Research 1991, 539(1):103-109.
36. Yang Y., Yang X.F., Wang Y.P., Tian Q., Wang X.C., Li H.L., Wang Q., Wang J.Z. Inhibition of protein phosphatases induces transport deficits and axonopathy. Journal of Neurochemistry 2007, 102(3):878-886.